Compare IMTE & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMTE | DRMA |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0M | 4.2M |
| IPO Year | 2016 | N/A |
| Metric | IMTE | DRMA |
|---|---|---|
| Price | $0.62 | $1.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 103.2K | ★ 1.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $0.59 |
| 52 Week High | $3.17 | $7.33 |
| Indicator | IMTE | DRMA |
|---|---|---|
| Relative Strength Index (RSI) | 43.72 | 44.96 |
| Support Level | $0.50 | $1.11 |
| Resistance Level | $0.82 | $2.29 |
| Average True Range (ATR) | 0.11 | 0.11 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 29.17 | 34.38 |
Integrated Media Technology Ltd is mainly engaged in the business of manufacture and sale of nano-coated plates for filters, the manufacture and sale of electronic glass, Halal certification and distribution of Halal products, and new energy products and services. It operates through the following segments: the sale of electronic glass, sales of air-filter products, sales of Halal products, NFT, corporate, provision of consultancy and provision of new energy products and solutions.
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology for patients suffering with acne. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin.